Today, AAI President Diana Moss joined House Judiciary Committee Democrats and the Congressional Progressive Caucus for a briefing on the effects of concentrated economic power on the economy and working Americans.
On December 7th, the American Antitrust Institute will host its third annual Airline Roundtable. Experts in antitrust and regulation from government, industry, advocacy, and academia will discuss major competition issues facing the airline industry and consumers of air travel. Recent antitrust and regulatory events in the airline industry make this an especially timely program, including: developments in opening domestic aviation markets to international competition; market entry issues surrounding airport infrastructure and access; and public and private enforcement regarding potentially anticompetitive agreements.
On December 7th, the AAI hosted its 3rd annual Airline Roundtable: Broadening the Lens on Airline Competition.
Today AAI, FWW, and NFU sent a joint letter to the U.S. Department of Justice regarding the proposed merger of Monsanto and Bayer. The joint letter is an addendum to a letter submitted by the three organizations on July 26th. It discusses the merger’s potential to enhance the ability and incentive for Monsanto and Bayer to integrate traits, seeds, and chemicals into proprietary systems or platforms that are closed to competition. The companies’ combined digital farming capabilities will likely facilitate such integration. Together with strengthened incentives for the appropriation and strategic competitive use of vast stores of farm data, these merger- related concerns have potentially adverse implications for competition, farmers, and consumers.
In a decision released today, a panel of the Third Circuit Court of Appeals upheld summary judgment for the defendant and raised the burden on plaintiffs relying on circumstantial evidence to prove a price-fixing conspiracy. A dissenting judge agreed with, and cited to, an amicus brief submitted by the American Antitrust Institute (AAI) that supported a less restrictive approach to evaluating circumstantial evidence of price fixing in oligopoly markets.
Diana Moss joined the Roosevelt Institute and the George Washington University Institute of Public Policy for a discussion regarding burgeoning areas in the antitrust debate. Moss's panel, Workers and Antitrust, debated antitrust and market power in the labor market.
In an amicus brief filed in the Eleventh Circuit Court of Appeals, the American Antitrust Institute (AAI) urged the court to reject the district court’s overly restrictive approach for allowing a price-fixing claim to reach a jury when the claim is based on an invitation to collude made during an investor earnings call.
The American Antitrust Institute (AAI) filed an amicus brief in the Third Circuit Court of Appeals in support of plaintiffs’ petition for rehearing and rehearing en banc. The petition seeks review of a decision by a panel of the court upholding summary judgment for defendants and dismissing plaintiffs’ pay-for-delay and sham litigation claims.
Today, the Chairman of the American Antitrust Institute (AAI) Board of Directors, Pamela Gilbert, announced the addition of Ellen Meriwether to the Board. “Ellen brings a rich and diverse background in antitrust enforcement, research, and scholarship to the AAI board,” said Gilbert. “Her expertise and insights will be invaluable to AAI's continuing leadership in competition policy and advocacy. I am thrilled that she is joining the board."
The American Antitrust Institute (AAI) notched another legal victory in its efforts to combat anticompetitive “reverse-payment” settlement agreements. In reversing the dismissal of complaints challenging settlements involving the brand name drugs Lipitor and Effexor, the Third Circuit followed the recommendations set forth in a pair of amicus briefs filed by AAI with 48 professors, and rejected a heightened pleading standard for reverse-payment claims. Effexor brief here. Lipitor brief here.